Regeneron Completes Acquiring Sanofi's Stake In Libtayo
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
With today's closing, Regeneron will now record 100% of global net sales and expenses for Libtayo.
Regeneron intends to update its full year 2022 financial guidance to reflect the Libtayo purchase during its second quarter 2022 earnings announcement in early August.
On May 31, 2022, Regeneron announced that it had successfully acquired Checkmate Pharmaceuticals, Inc. for a total equity value of approximately $250 million.
As a result of the Checkmate acquisition, Regeneron expects to record in the second quarter of 2022 an acquired in-process research and development (IPR&D) charge of approximately $195 million, which would negatively impact GAAP and non-GAAP diluted earnings per share by approximately $1.70.
Regeneron Pharma Q2 Results Top Estimates - Update
Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
Sanofi And Biovac Ink Manufacturing Partnership To Make Inactivated Polio Vaccines In Africa
Sanofi, OpenAI To Build AI Software To Boost Drug Development
Sanofi Q1 Profit Weak, But Sales Rise; Backs FY24 View; Stock Up
Regeneron Pharma Q4 Results Top Estimates - Update
